Switching to next-generation medications Rather than cycling between existing options, the rapidly evolving GLP-1 landscape offers genuinely new medications that may better serve people who have plateaued on semaglutide or tirzepatide
Patients treated with Ozempic were 24% less likely to develop kidney failure (dialysis, transplantation, or an eGFR of 50% decline), or death from kidney-related or cardiovascular causes Non-alcoholic fatty liver disease (NAFLD), aka metabolic dysfunctionassociated steatohepatitis (MASH), often goes undetected but is closely linked with obesity and metabolic dysfunction
As we age, however, our bodies naturally produce less glutathione, and factors like stress, lack of sleep, and exposure to pollutants can further reduce its levels
It is particularly suitable for postmenopausal osteoporosis, age-related bone loss, osteoarthritis, sports bone injury, and bone loss during the weight loss period
Corrigendum to Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease EBioMedicine 47 (2019) 446456
